List of Excipients in Branded Drug MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION

« Back to Dashboard

Generic Drugs Containing MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	medroxyprogesterone acetate	24201-150	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	medroxyprogesterone acetate	24201-150	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	medroxyprogesterone acetate	24201-150	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	METHYLPARABEN
1	POLYETHYLENE GLYCOL 3350

Medroxyprogesterone Acetate Injectable Suspension: Excipient Strategy and Commercial Opportunities

Last updated: October 18, 2026

Medroxyprogesterone acetate injectable suspension is a mature contraceptive product with a low-complexity active ingredient but meaningful formulation barriers. The commercial opportunity is concentrated in ready-to-use sterile suspensions, subcutaneous delivery, preservative optimization, prefilled devices, global heat-stable products, and manufacturing technologies that improve redispersibility and dose uniformity.

The reference products are Depo-Provera CI, a 150 mg/mL intramuscular suspension, and Depo-subQ Provera 104, a 104 mg/0.65 mL subcutaneous suspension marketed by Pfizer. Both rely on an aqueous vehicle containing polyethylene glycol 3350, polysorbate 80, sodium chloride, preservatives, and water for injection, with product-specific differences in concentration, container, device, and administration route.[1,2]

What is medroxyprogesterone acetate injectable suspension?

Medroxyprogesterone acetate, or MPA, is a synthetic progestin used in long-acting contraception and other hormone-sensitive indications. Injectable products form a depot at the administration site. The drug is released gradually as the suspended particles dissolve and are absorbed.

Product	Strength	Route	Presentation	Commercial role
Depo-Provera CI	150 mg/mL	Intramuscular	Vial or prefilled presentation depending on market	Established long-acting contraceptive
Depo-subQ Provera 104	104 mg/0.65 mL	Subcutaneous	Prefilled Uniject-style injection system	Self-administration and lower-volume delivery
Generic MPA injectable suspension	Typically 150 mg/mL	Intramuscular	Vial, ampoule, or syringe	Price competition and institutional supply
Potential differentiated products	Variable	Subcutaneous, intramuscular, or depot systems	Prefilled syringe, autoinjector, or alternative container	Lifecycle management and access expansion

The formulation challenge is not simply dissolving MPA. MPA has limited water solubility, so the product must maintain a stable, injectable suspension with controlled particle size, acceptable syringeability, consistent delivered dose, and predictable depot behavior.

What excipients are used in medroxyprogesterone acetate injectable suspension?

The reference formulation uses excipients that perform distinct physical, chemical, and manufacturing functions.

Excipient class	Reference example	Primary function	Key development concern
Suspending or viscosity-modifying vehicle	Polyethylene glycol 3350	Maintains suspension characteristics and influences sedimentation and release	Viscosity, injection force, osmolality, particle wetting
Surfactant	Polysorbate 80	Improves wetting and dispersion of hydrophobic MPA particles	Oxidation, peroxide formation, particle interaction, subvisible particles
Tonicity agent	Sodium chloride	Adjusts osmolality	Osmolality and tissue tolerability
Preservative	Methylparaben and, in some presentations, propylparaben	Controls microbial growth in multidose products	Local tolerability, extractables, regulatory acceptability
Aqueous phase	Water for injection	Sterile continuous phase	Bioburden, endotoxin, container compatibility
Active phase	Micronized MPA	Provides the depot drug load	Particle-size distribution, polymorphism, aggregation, dissolution rate

The excipient system is relatively conventional, which limits opportunities for a new supplier to win solely through substitution. The stronger commercial position comes from improving performance while preserving the reference product's critical quality attributes.

How does polyethylene glycol 3350 affect the suspension?

Polyethylene glycol 3350 acts as a hydrophilic vehicle and contributes to suspension stability. It can influence sedimentation rate, redispersibility, viscosity, injection force, and the rate at which MPA particles are exposed to physiological fluids.

A higher-viscosity vehicle may reduce settling but can create problems during filling and administration. A lower-viscosity system may improve syringeability but increase sedimentation and dose nonuniformity. The target is a formulation that remains homogeneous during the labeled handling period and can be redispersed with controlled agitation.

What is the role of polysorbate 80?

Polysorbate 80 improves wetting of hydrophobic MPA particles and supports dispersion in the aqueous vehicle. Its risks include oxidative degradation, peroxide generation, interaction with drug particles, and formation of subvisible particles.

A formulation developer should control:

• Peroxide and aldehyde levels in the excipient.
• Storage temperature and oxygen exposure.
• Surfactant adsorption to container surfaces.
• Interaction with elastomeric closures.
• Particle-size changes after agitation and accelerated storage.

Polysorbate 80 substitution with another nonionic surfactant could create a differentiated product, but it would require a full assessment of local tolerability, suspension performance, extractables, degradation products, and bioequivalence.

Are preservatives commercially important?

Preservatives matter most for multidose vials. A single-dose vial or prefilled syringe can support a preservative-reduced or preservative-free positioning, but the change affects microbiological control, manufacturing cost, packaging, and regulatory strategy.

Methylparaben and propylparaben are established preservative options in injectable products, but their concentrations and combinations require justification under current regulatory expectations. A preservative-free presentation may have commercial value in patients with preservative sensitivity and in self-administration, although the benefit must be balanced against higher container-closure and manufacturing requirements.

What formulation patents protect medroxyprogesterone acetate injectable suspension?

Protection for a legacy MPA injectable product is likely to be distributed across active-ingredient patents, formulation patents, delivery-device rights, manufacturing processes, and method-of-use claims. The original composition-of-matter protection for MPA is long expired. The commercial patent question is therefore product-specific.

Potential protection category	Typical claim subject	Strategic relevance
Formulation composition	MPA concentration, vehicle, surfactant, preservatives, particle size	Can delay direct formulation substitution
Particle engineering	Micronization, crystal form, morphology, agglomeration control	May affect release and bioequivalence
Depot release	Composition or particle attributes that control duration	Important for long-acting contraception
Device	Prefilled syringe, autoinjector, needle shield, dose-delivery mechanism	Can create rights separate from the drug formulation
Manufacturing	Sterilization, aseptic mixing, filling, homogenization, suspension control	Creates know-how and process barriers
Method of use	Dosing interval, injection route, population, or self-administration	May support use-specific market protection

An ANDA applicant would generally need to evaluate the FDA Orange Book listing for the relevant reference product and certify against listed patents under Paragraph I, II, III, or IV. Paragraph IV certification can trigger patent litigation if the reference-product sponsor sues within the statutory period.[3,4]

Current commercial diligence should separate:

1. Patents listed for the 150 mg/mL intramuscular product.
2. Patents listed for the 104 mg/0.65 mL subcutaneous product.
3. Device patents covering the prefilled delivery system.
4. Unlisted process and manufacturing know-how.
5. Foreign rights, which may differ materially from U.S. rights.

When does medroxyprogesterone acetate injectable suspension lose exclusivity?

The core MPA molecule is no longer protected by new chemical entity exclusivity. Market entry is governed by product-specific patents, FDA regulatory exclusivity, manufacturing capability, and state or country-level procurement requirements.

Exclusivity type	Relevance to MPA injectable suspension
New chemical entity exclusivity	Expired for legacy MPA
Five-year NCE protection	Not available for an old active ingredient
Three-year clinical investigation exclusivity	Possible only for qualifying new clinical work and a qualifying change
Orphan-drug exclusivity	Generally not the central protection for contraceptive MPA products
Pediatric exclusivity	Product-specific and dependent on an FDA grant
Listed patent term	Depends on each patent's filing date, patent-term adjustment, and terminal disclaimer
Device or combination-product patents	May continue after core drug exclusivity expires
Trade secrets	Can remain commercially relevant without a public expiration date

A generic applicant should not assume that the absence of a current molecule patent eliminates risk. The more relevant barriers may be suspension performance, device rights, injectable manufacturing validation, and the need to demonstrate bioequivalence for a complex suspension.

What FDA regulatory pathway applies to generic MPA suspension?

A 505(j) ANDA is the usual pathway for a product that matches the reference drug in active ingredient, dosage form, strength, route, labeling framework, and relevant pharmaceutical characteristics.[5]

A 505(b)(2) application may be more suitable when the proposed product changes a clinically meaningful element, such as:

• Intramuscular delivery to subcutaneous delivery.
• A new concentration or dosing volume.
• A materially different excipient system.
• A new delivery device.
• A preservative-free presentation requiring new clinical justification.
• A modified release profile.
• A new indication or administration schedule.

For an injectable suspension, the regulatory package will typically emphasize:

• Comparative composition.
• Particle-size distribution.
• Crystal form and morphology.
• Redispersibility.
• Sedimentation and settling behavior.
• Viscosity and injection force.
• Assay and content uniformity.
• Sterility and bacterial endotoxins.
• Extractable and leachable substances.
• Container-closure integrity.
• In vitro release and comparative dissolution.
• Pharmacokinetic or clinical bridging where required.

The FDA's product-specific guidance and reference-product standards should control the development plan rather than a simple liquid-injection bioequivalence model.[6]

What excipient strategies offer the strongest commercial opportunities?

1. Preservative-free single-dose suspension

A preservative-free vial or prefilled syringe can target hospitals, public-health programs, and patients requiring reduced excipient exposure. The opportunity depends on achieving robust sterility assurance and container-closure integrity without relying on multidose preservation.

The product would need a clear advantage over the established presentations, such as simplified use, lower adverse-event concern, or better compatibility with self-administration.

2. Ready-to-use subcutaneous product

The subcutaneous route reduces dependence on trained intramuscular administration and supports community distribution or self-injection. The key formulation requirement is lower injection force at the same time as acceptable depot performance.

A smaller injection volume, optimized particle size, lower viscosity, and a device with controlled delivery force could support a differentiated product.

3. Prefilled syringe and autoinjector compatibility

Device integration is a major commercial opportunity because suspension products can clog needles, settle during storage, or require vigorous agitation. A successful presentation would need validated performance after shipping, temperature cycling, and extended storage.

Important design variables include:

• Needle gauge and length.
• Dead volume.
• Agitation requirements.
• Delivery time.
• Plunger force.
• Dose accuracy.
• Human-factors performance.
• Compatibility with suspension viscosity and particle size.

4. Excipient systems that reduce polysorbate-related degradation

A lower-peroxide surfactant system or alternative wetting strategy could improve chemical stability and reduce subvisible particle formation. The replacement must maintain MPA dispersion without compromising tissue tolerability or release behavior.

This is a technically attractive but regulatory-intensive opportunity. A surfactant change can affect pharmacokinetics, local reaction risk, and bioequivalence.

5. Heat-stable and low-resource-market formulations

MPA is used in public-health and family-planning programs where cold-chain reliability, shipping cost, and storage conditions affect procurement decisions. A suspension with stronger temperature stability, lower agitation sensitivity, and robust packaging could command value even without a novel active ingredient.

Commercial differentiation could include:

• Extended temperature excursions.
• Improved sedimentation control.
• Reduced preparation time.
• Lower breakage risk.
• Simplified disposal.
• Unit-dose packaging for outreach programs.

6. Manufacturing platforms for generic suppliers

The most defensible opportunity may be process know-how rather than a new excipient. A supplier that can reliably produce a narrow MPA particle-size distribution, uniform filling, and stable redispersion can reduce a generic manufacturer's development risk.

Relevant process controls include wetting order, mixing energy, homogenization, deaeration, hold time, filling conditions, and in-process suspension uniformity.

How strong is the patent estate for MPA injectable suspension?

The estate is likely weaker at the active-ingredient level and stronger at the product and delivery-system level. A commercial assessment should score each layer separately.

Patent layer	Relative exposure	Reason
MPA composition of matter	Low	Legacy progestin with long-expired basic compound protection
Basic 150 mg/mL suspension	Moderate to low	Mature product category and potential prior art
Specific excipient combinations	Moderate	Risk depends on claim scope and patent status
Subcutaneous 104 mg presentation	Moderate	Route, dose, device, and clinical-use claims may overlap
Prefilled delivery system	Moderate to high	Device claims may create separate barriers
Manufacturing process	High practical barrier, even if patent risk is low	Aseptic suspension manufacturing is difficult to replicate
Method-of-use claims	Variable	Depends on indication, population, interval, and patent term

Patent strength should be evaluated by claim breadth, expiration, prosecution history, written-description support, enablement, prior art, and the likelihood that a competing formulation would read on the claims. A narrow excipient claim may have limited commercial value if a competitor can change one excipient without affecting performance.

Which companies and products compete with MPA injectable suspension?

Competition comes from both other injectable contraceptives and noninjectable long-acting methods.

Competitor	Delivery	Competitive advantage
Norethisterone enanthate	Intramuscular injection	Alternative progestin and shorter dosing interval in some markets
Levonorgestrel implants	Subdermal implant	Long duration without repeated injections
Etonogestrel implant	Subdermal implant	Highly effective long-acting option
Levonorgestrel intrauterine systems	Intrauterine	Long duration and local hormone delivery
Copper intrauterine devices	Intrauterine	Hormone-free contraception
Combined hormonal methods	Oral, transdermal, or vaginal	Broader user control and more frequent administration
MPA biosimilar-style products	Intramuscular or subcutaneous	Lower price and broader procurement access

MPA retains commercial relevance where injection-based contraception is preferred, provider access is limited, or low-frequency dosing is valued. Its weaknesses include repeat injection requirements, concerns about delayed return to fertility, and the need for trained administration for intramuscular products.

What generic launch scenarios exist?

Scenario 1: Conventional intramuscular generic

This is the lowest-cost route but also the most exposed to price competition. Success depends on supply reliability, manufacturing scale, and tender access. A new entrant would need strong suspension uniformity and reliable sterile filling more than a novel excipient profile.

Scenario 2: Subcutaneous lifecycle product

A subcutaneous product can compete through administration convenience and device integration. It may require a 505(b)(2) strategy or a more complex bridging program, but the potential commercial differentiation is stronger.

Scenario 3: Preservative-free unit-dose product

This product could target institutions and patients with excipient concerns. The opportunity is narrower, but price erosion may be less severe if the presentation solves a procurement or handling problem.

Scenario 4: Global-access formulation

A heat-stable, low-cost, unit-dose product could compete in public-sector programs. The primary barriers would be manufacturing validation, regulatory registrations, donor or tender qualification, and supply-chain performance.

What licensing opportunities exist?

Licensing opportunities are most credible in four areas:

1. A prefilled or autoinjector platform validated for suspensions.
2. A particle-engineering process that improves redispersibility and dose uniformity.
3. A preservative-free multidose or unit-dose container-closure system.
4. A regional commercialization partnership for public-health procurement.

A drug company would likely value a partner that can provide regulatory-ready manufacturing rather than an isolated excipient. The strongest deal structure would link upfront or milestone payments to successful device compatibility, bioequivalence, FDA acceptance, and first commercial supply.

What are the main manufacturing and IP barriers?

The key barriers are process reproducibility and injectable quality control. MPA suspension production requires control over particle size, wetting, agglomeration, mixing, filling, and settling during storage.

Manufacturing risks include:

• Dose variation caused by sedimentation during filling.
• Needle blockage from agglomerates.
• High injection force from excessive viscosity.
• Polysorbate degradation.
• Preservative adsorption or loss.
• Container-closure extractables.
• Inadequate redispersion after shipping.
• Sterility failures in high-viscosity suspension processing.
• Batch-to-batch variation in MPA particle morphology.

These risks can create a stronger practical barrier than patent expiration. A company with a mature sterile-suspension platform may reach the market faster than a company with a superficially similar excipient formula.

Key Takeaways

• MPA injectable suspension is a mature product with limited active-ingredient patent value and continuing formulation and device complexity.
• Polyethylene glycol 3350, polysorbate 80, sodium chloride, preservatives, and water for injection define the reference excipient architecture.
• The strongest opportunities are subcutaneous delivery, preservative-free unit doses, prefilled devices, heat-stable products, and manufacturing platforms.
• A conventional intramuscular generic is commercially feasible but likely exposed to price erosion.
• Subcutaneous and device-integrated products offer greater differentiation but may require a 505(b)(2) or more extensive bridging strategy.
• Patent diligence should cover formulation claims, device claims, method-of-use claims, Orange Book listings, and unlisted manufacturing know-how.
• The main technical risks are particle-size control, redispersibility, injection force, sterility, preservative performance, and container compatibility.

FAQs About Medroxyprogesterone Acetate Injectable Suspension

Is medroxyprogesterone acetate injectable suspension a biologic?

No. MPA is a small-molecule synthetic progestin. Products are regulated as drug products, not biologics, and biosimilar pathways do not apply.

Can a generic manufacturer change the excipients?

A generic manufacturer may use different excipients if the product remains pharmaceutically and clinically equivalent and meets FDA requirements. Excipients that change suspension behavior, local tolerability, or release may require additional evidence.

Is a preservative-free MPA injection commercially attractive?

Yes, particularly for single-dose packaging, self-administration, institutional use, and patients seeking to avoid parabens. The commercial value depends on whether the higher packaging and manufacturing cost creates a measurable clinical or procurement benefit.

Does a subcutaneous MPA product automatically qualify for an ANDA?

No. A route, dose, device, or release change can prevent a product from being an uncomplicated ANDA. The appropriate pathway depends on the extent of difference from the reference product and the evidence required to support approval.

What is the most defensible competitive advantage in this market?

A validated combination of stable particle engineering, low injection force, reliable redispersion, device compatibility, and scalable sterile manufacturing is more defensible than a minor excipient substitution alone.

References

1. Pfizer Inc. (2023). Depo-Provera CI medroxyprogesterone acetate injectable suspension, USP prescribing information. U.S. Food and Drug Administration.

2. Pfizer Inc. (2023). Depo-subQ Provera 104 medroxyprogesterone acetate injectable suspension prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Patent certification and exclusivity provisions for abbreviated new drug applications. FDA.

5. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Content and format. FDA.

6. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. FDA.